Efficacy and Safety of IL-17 and JAK Inhibitors in Ankylosing Spondylitis: A Systematic Review and Network Meta-Analysis

塞库金单抗 医学 托法替尼 伊克泽珠单抗 强直性脊柱炎 安慰剂 内科学 随机对照试验 荟萃分析 银屑病性关节炎 类风湿性关节炎 替代医学 病理
作者
Xiaojuan Zhao,Menghao Li,Xinhui Zhang,Yunfei Tian,Dan Li,Yongjing Wang,Yonghong Zhao,Qianying Li,Y.-F. Qi,Xiuju Liu
出处
期刊:International Archives of Allergy and Immunology [S. Karger AG]
卷期号:: 1-18
标识
DOI:10.1159/000544752
摘要

Objective: The aim of this study was to compare the clinical efficacy and safety of interleukin-17 inhibitors and Janus kinase inhibitors in the treatment of ankylosing spondylitis based on a network meta-analysis. Methods: According to the search strategy, systematic retrievals were conducted in PubMed, Embase, Web of Science, the Cochrane Register of Clinical Trials, Scopus, and website ClinicalTrials.gov, from the establishment to December 8, 2023. Randomized controlled trials (RCTs) of interleukin-17 inhibitors and Janus kinase inhibitors for the treatment of ankylosing spondylitis were selected according to the inclusion and exclusion criteria. The included studies were evaluated for quality using the Cochrane Risk of Bias Assessment Tool, and data were statistically analyzed using Software Stata 16.0, to compare the effectiveness and safety differences in all interventions. Results: A total of 18 RCTs involving 3968 subjects were included in this study. The interventions were ranked from best to worst in terms of ASAS20: netakimab 120 mg > filgotinib 200 mg > tofacitinib 5 mg> brodalumab 210 mg >upadacitinib 15 mg >bimekizumab 160 mg > secukinumab 300 mg> ixekizumab 80 mg Q4W > secukinumab 150 mg > secukinumab 150 mg no LD> placebo, netakimab 120 mg outperformed all other interventions and the difference was statistically significant. The interventions were ranked from best to worst in terms of ASAS40: netakimab 120 mg > tofacitinib 5 mg > secukinumab 150 mg > secukinumab 300 mg > upadacitinib 15 mg > bimekizumab 160 mg> ixekizumab 80 mg Q4W > filgotinib 200 mg > brodalumab 210 mg > secukinumab 150 mg no LD > placebo, netakimab 120 mg outperformed all other interventions and was statistically significant (except the intervention of filgotinib 200 mg). In terms of AEs and SAEs, there was no statistical significance among all interventions. Conclusions: The results of the network meta-analysis showed that netakimab 120mg ranked relatively high in outcome of ASAS20 and ASAS40. All treatments with IL-17 and JAK inhibitors were generally safe and well tolerated. However, the two included netakimab clinical studies may have limitations. Therefore, the therapeutic agents should be carefully selected in clinical treatment. Moreover, the efficacy and safety of netakimab remain to be further analyzed in studies with larger sample sizes and longer follow-up times.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小赵童鞋完成签到,获得积分10
1秒前
科研通AI2S应助21采纳,获得10
4秒前
善学以致用应助James采纳,获得10
5秒前
6秒前
星业辰完成签到,获得积分10
8秒前
暴躁小兔完成签到,获得积分10
8秒前
勤恳完成签到,获得积分10
9秒前
10秒前
11秒前
bkagyin应助幽默钢笔采纳,获得10
13秒前
13秒前
18秒前
terence完成签到,获得积分10
19秒前
在水一方应助带帽采纳,获得10
19秒前
19秒前
20秒前
lailai完成签到 ,获得积分10
21秒前
科研通AI5应助诚心的平松采纳,获得10
23秒前
James发布了新的文献求助10
25秒前
研友_LBKOgn完成签到,获得积分20
26秒前
Ava应助CartGo采纳,获得10
28秒前
俏皮的采波完成签到,获得积分10
28秒前
JamesPei应助吕妍采纳,获得30
31秒前
aaa完成签到 ,获得积分10
33秒前
21发布了新的文献求助10
33秒前
冷傲迎梦完成签到,获得积分20
34秒前
不倦应助1234采纳,获得10
36秒前
阿南完成签到 ,获得积分10
38秒前
zhong完成签到,获得积分10
39秒前
41秒前
kxy完成签到,获得积分10
43秒前
美好的思松完成签到,获得积分10
44秒前
45秒前
土豆完成签到,获得积分10
45秒前
科研通AI5应助真凉大魔王采纳,获得10
47秒前
生动听筠发布了新的文献求助30
47秒前
陈瑶完成签到,获得积分10
48秒前
xiaolu发布了新的文献求助10
50秒前
赶紧毕业发布了新的文献求助10
51秒前
52秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 820
England and the Discovery of America, 1481-1620 600
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3572635
求助须知:如何正确求助?哪些是违规求助? 3142841
关于积分的说明 9449037
捐赠科研通 2844177
什么是DOI,文献DOI怎么找? 1563386
邀请新用户注册赠送积分活动 731723
科研通“疑难数据库(出版商)”最低求助积分说明 718679